Letter to the EditorResponse to “Non-vitamin K antagonist oral anticoagulants (NOACs) in preventing thromboembolism in atrial fibrillation patients with moderate to severe mitral stenosis: Results from a pilot trial”
References (10)
- et al.
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
J. Am. Coll. Cardiol.
(2019) - et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Lancet.
(2014) - et al.
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease
J. Am. Coll. Cardiol.
(2017) - et al.
Long-term oral anticoagulation for atrial fibrillation in low and middle income countries
Indian Heart J.
(2021) - et al.
The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation
Am. Heart J.
(2020)
There are more references available in the full text version of this article.
Cited by (0)
© 2022 Published by Elsevier B.V.